Washington Senate approves bill to maintain DOC stockpile of abortion medications after heated debate
Loading...
Summary
After extensive debate and failed amendment attempts, the Washington State Senate passed substitute S.B. 5917 to continue a Department of Corrections stockpile of abortion medications and allow distribution to providers; final roll-call was 32 yeas, 17 nays.
The Washington State Senate on Feb. 10 passed substitute Senate Bill 5,917 to allow the Department of Corrections (DOC) to maintain and distribute a stockpile of abortion medications and to revise distribution rules, after lengthy floor debate and multiple failed amendments.
Supporters led by Senator Bateman said the stockpile preserves access to mifepristone and misoprostol amid shifting federal court decisions and practical supply challenges. "Without this stockpile, we cannot ensure that people in Washington can actually get access to this medication, which is safe," Bateman said, urging colleagues to vote yes.
Opponents warned the bill could make the DOC pharmacy act as a wholesale supplier beyond its original purpose. Senator Fortunato argued amendment proposals that would have required cost recovery and limited distribution to Washington residents were necessary to prevent Washington taxpayers from subsidizing out-of-state distribution. "We're gonna be buying abortion pills through the Department of Corrections pharmacy ... and now they are gonna become a wholesale supplier in effect to basically any health organization that asks for it," Fortunato said.
Lawmakers debated a string of amendments that sought to require reimbursement, add warning-label language, limit distribution to in-state residents or to DOC inmates only, and remove an emergency clause. Most of those amendments were rejected on the floor. Senator Christian pressed for stronger labeling and fiscal guardrails, while Senator Wilson (Jeff) defended the state's approach and the DOC pharmacy's capacity to manage large pharmaceutical inventories.
Senator Frame, a supporter, explained clinical and access considerations: "The exact same combination [mifepristone and misoprostol] is used to manage a miscarriage," she said, recounting personal difficulty obtaining mifepristone and arguing the bill protects women's health care and miscarriage management.
During debate, several senators raised differing estimates of fiscal and medical risk. Senator McKeown said research shows "abortion pills result in serious complications in 1 out of every 10 women," a figure contested on the floor; opponents used such claims to press for limits on distribution and greater labeling.
After debate, the chamber advanced the substitute bill and proceeded to a roll-call final passage vote. The secretary recorded a final tally of 32 yeas and 17 nays; the clerk announced the bill had received a constitutional majority and was declared passed.
What happens next: The bill’s title will be the title of the act and, if enacted, will allow the DOC pharmacy to continue purchasing and distributing the medications under the terms set in the enacted substitute. The transcript shows multiple unsuccessful amendments seeking to restrict distribution or require cost recovery; the enacted text will reflect which of those, if any, were adopted during the amendment process.
Votes and formal action: Substitute S.B. 5,917 was advanced to third reading and placed on final passage and was declared passed (final roll-call 32–17).
